Hanba Yoshiyuki, Ooura Maki, Negi Shigeo, Shigematsu Takashi
Wakayama Medical University, Division of Nephrology and Blood Purification Medicine, Japan.
Clin Calcium. 2008 Jan;18(1):81-8.
In this part, we reports the experience of treatment by calcimimetics for 3 hemodialyzed patients with refractory secondary hyperparathyroidism. They purchased own expense, and used "Cinacalcet" as calcimimetics (Sensipar(R) 30 mg/tablet, by AMGEN co. Ltd. in USA) . Serum Ca, P, and intact-PTH decreased certainly in 3 cases after cinacalcet therapy. Especially the reduction of intact-PTH is obviously. The any adverse effect did not observed by 30 mg/tablet/day prescription except mild epigastralgia in a case. We were able to experience the marked suppressive effect on parathyroid gland by cinacalcet as calcimimetics in Japanese patients with refractory secondary hyperparathyroidism undergoing hemodialysis.
在本部分中，我们报告了3例血液透析患者使用拟钙剂治疗难治性继发性甲状旁腺功能亢进的经验。药物为患者自费购买，使用“西那卡塞”作为拟钙剂（Sensipar® 30mg/片，由美国安进有限公司生产）。3例患者在使用西那卡塞治疗后，血清钙、磷和完整甲状旁腺激素水平均有明显下降。尤其是完整甲状旁腺激素的降低更为显著。每日30mg/片的剂量除1例患者出现轻度上腹痛外，未观察到其他不良反应。在接受血液透析的日本难治性继发性甲状旁腺功能亢进患者中，我们观察到西那卡塞作为拟钙剂对甲状旁腺有显著的抑制作用。
